Pacific Biosciences of California, Inc.
PACB
$1.36
$0.107.94%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 39.77M | 37.15M | 39.22M | 39.97M | 36.01M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 39.77M | 37.15M | 39.22M | 39.97M | 36.01M |
| Cost of Revenue | 24.88M | 30.11M | 31.35M | 26.76M | 26.45M |
| Gross Profit | 14.89M | 7.04M | 7.88M | 13.21M | 9.56M |
| SG&A Expenses | 36.18M | 40.17M | 56.04M | 36.85M | 45.88M |
| Depreciation & Amortization | 1.02M | 366.39M | 6.85M | 6.85M | 6.85M |
| Other Operating Expenses | -- | 4.07M | 998.00K | -- | -- |
| Total Operating Expenses | 84.60M | 469.79M | 128.60M | 95.97M | 117.66M |
| Operating Income | -44.83M | -432.63M | -89.38M | -56.01M | -81.65M |
| Income Before Tax | -41.90M | -426.38M | 2.69M | -60.73M | -173.32M |
| Income Tax Expenses | 35.00K | -302.00K | 316.00K | -- | -- |
| Earnings from Continuing Operations | -41.93M | -426.08M | 2.37M | -60.73M | -173.32M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -41.93M | -426.08M | 2.37M | -60.73M | -173.32M |
| EBIT | -44.83M | -432.63M | -89.38M | -56.01M | -81.65M |
| EBITDA | -41.15M | -61.11M | -79.68M | -44.96M | -71.30M |
| EPS Basic | -0.14 | -1.44 | 0.01 | -0.22 | -0.64 |
| Normalized Basic EPS | -0.09 | -0.91 | -0.20 | -0.12 | -0.18 |
| EPS Diluted | -0.14 | -1.44 | 0.01 | -0.22 | -0.64 |
| Normalized Diluted EPS | -0.09 | -0.91 | -0.18 | -0.12 | -0.18 |
| Average Basic Shares Outstanding | 300.16M | 296.86M | 283.00M | 272.92M | 272.39M |
| Average Diluted Shares Outstanding | 300.16M | 296.86M | 306.89M | 272.92M | 272.39M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |